Patents Assigned to ONO
-
Patent number: 10882855Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.Type: GrantFiled: May 10, 2019Date of Patent: January 5, 2021Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan
-
Publication number: 20200407408Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: March 7, 2019Publication date: December 31, 2020Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
-
Publication number: 20200392110Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: ApplicationFiled: April 24, 2020Publication date: December 17, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
-
Publication number: 20200390137Abstract: The method extracts an extract containing sea cucumber saponins. The extract is separated from sea cucumber meat exclusively by a specific heat treatment without conducting any chemical treatment with the use of an enzyme, ethanol, etc. The method includes: a step for heating sea cumbers from a starting temperature to a target heating temperature by a first temperature gradient; and a step for decreasing the temperature by a second temperature gradient that is gentler than the first temperature gradient to thereby extract the sea cucumber extract. The sea cucumber extract is stored as a sea cucumber extract material in the form of a liquid concentrate, etc. Then an appropriate amount of the sea cucumber extract material is added to, for example, another sea cucumber extract material having been separated and extracted from sea cucumbers with a lower saponin content.Type: ApplicationFiled: August 18, 2018Publication date: December 17, 2020Applicants: ISF LLC, Iwate Prefecture, Iwate Medical University, Sanshou Inc, Ono Foods Co. LtdInventors: Akira Yano, Mitsuo Kishi, Takao Sawai, Takao Sasaki, Akio Ono
-
Patent number: 10835520Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.Type: GrantFiled: October 1, 2018Date of Patent: November 17, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
-
Patent number: 10836747Abstract: The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a prophylactic and/or therapeutic agent for immune diseases, cancer and the like, a crystal thereof, and a pharmaceutical composition thereof.Type: GrantFiled: January 25, 2018Date of Patent: November 17, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takahiro Nekado, Hideomi Kijima, Shizuka Ono, Toshihiko Nishiyama
-
Patent number: 10815233Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.Type: GrantFiled: December 19, 2019Date of Patent: October 27, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Motoyuki Tanaka, Takashi Kondo, Yasuo Hirooka, Taihei Nishiyama, Atsushi Hiramatsu, Tomoyuki Koda, Sho Kouyama
-
Publication number: 20200330453Abstract: A therapeutic agent for treatment of solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention has strong antitumor effect and is therefore useful for treatment of solid cancers.Type: ApplicationFiled: October 12, 2018Publication date: October 22, 2020Applicants: ONO PHARMACEUTICAL CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Koichi TAKAYAMA, Tadaaki YAMADA, Tomoko YASUHIRO, Kohei TANAKA
-
Patent number: 10807981Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: June 25, 2019Date of Patent: October 20, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20200325453Abstract: To produce and/or maintain naïve pluripotent stem cells capable of highly expressing genes important for maintaining an undifferentiated state, which could not be achieved by known methods for producing pluripotent stem cells. The present invention can produce naïve pluripotent stem cells capable of maintaining an undifferentiated state by introducing and allowing transient expression of six genes (Oct3/4, Klf4, c-Myc, Sox2, Nanog, and Klf2) among the so-called initializing factors, and further performing culturing in a medium containing LIF, an MEK inhibitor, a GSK3 inhibitor, a cAMP production promoter, a TGF-? inhibitor and a PKC inhibitor. Thus, the problem of the present invention can be solved.Type: ApplicationFiled: June 30, 2020Publication date: October 15, 2020Applicants: ONO PHARMACEUTICAL CO., LTD., KEIO UNIVERSITYInventors: Hideyuki OKANO, Seiji Shiozawa, Fumihiko Kisa
-
Publication number: 20200317783Abstract: A prophylactic, symptom progress-suppressive, recurrence-suppressive and/or therapeutic agent for autoimmune disease or graft-versus-host disease, comprising a PD-1/CD19 bispecific antibody or antibody fragment thereof having a first arm capable of specifically binding to PD-1 and a second arm capable of specifically binding to CD19, as an active ingredient. The PD-1/CD19 bispecific antibody exhibits suppressive effect on proliferation of activated B cells and suppressive effect on production of immunoglobulin, and also has an effect of suppressing production of cytokine from memory T cells.Type: ApplicationFiled: October 5, 2018Publication date: October 8, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA
-
Patent number: 10765676Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.Type: GrantFiled: April 5, 2019Date of Patent: September 8, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Jun Takeuchi, Satoshi Itadani, Kazuya Hashimura, Masahiro Ikura, Masato Higashino, Tetsuya Yasuhiro, Takeshi Nagaura
-
Patent number: 10738280Abstract: To produce and/or maintain naïve pluripotent stem cells capable of highly expressing genes important for maintaining an undifferentiated state, which could not be achieved by known methods for producing pluripotent stem cells. The present invention can produce naïve pluripotent stem cells capable of maintaining an undifferentiated state by introducing and allowing transient expression of six genes (Oct3/4, Klf4, c-Myc, Sox2, Nanog, and Klf2) among the so-called initializing factors, and further performing culturing in a medium containing LIF, an MEK inhibitor, a GSK3 inhibitor, a cAMP production promoter, a TGF-? inhibitor and a PKC inhibitor. Thus, the problem of the present invention can be solved.Type: GrantFiled: March 17, 2016Date of Patent: August 11, 2020Assignees: ONO PHARMACEUTICAL CO., LTD., KEIO UNIVERSITYInventors: Hideyuki Okano, Seiji Shiozawa, Fumihiko Kisa
-
Patent number: 10730830Abstract: A compound of general formula (I-1): wherein the symbols are defined in the specification, has a selective S1P5 receptor binding activity and modulates the function of an S1P5 receptor, and can therefore be a therapeutic agent for a S1P5-mediated disease, for example, neurodegenerative diseases such as schizophrenia, Binswanger's disease and the like.Type: GrantFiled: January 27, 2017Date of Patent: August 4, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Toshihide Watanabe, Kensuke Kusumi, Yuichi Inagaki
-
Publication number: 20200236883Abstract: An automatic and modular system for handling trays (32) used for containing plants or the like to be grown through hydroponic, or aeroponic, or aquaponic farming, comprises a first module (30) with a quadrangular plan and a vertical arrangement delimited by respective vertical supports (31), said first module (30) comprising two lateral zones, each of which includes a plurality of substantially horizontal and overlapping supporting seats or guides (37, 37?) for trays (32), and a central zone in which a vertical tray transfer device (33) operates, slidably along a vertical axis (Z) arranged on a movement means activated by motorization assemblies (34) able to translate said vertical transfer device (33) from a lowered position to a raised position for bringing itself to each tray (32) and vice versa, said vertical transfer device (33) being provided with a resting shelf (33?) for a tray (32) and with a first means adapted to translate along a first horizontal axis (Y) said tray from and towards a respective seType: ApplicationFiled: July 30, 2018Publication date: July 30, 2020Applicant: ONO EXPONENTIAL FARMING S.R.L.Inventor: Thomas Ambrosi
-
Patent number: 10717738Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.Type: GrantFiled: July 7, 2017Date of Patent: July 21, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Steve Courtney, Chris Yarnold, Stuart Flanagan, Gareth Brace, John Barker, Osamu Ichihara, Elise Gadouleau, Anthony Richardson, Takashi Kondo, Akira Imagawa, Shingo Nakatani, Ryo Suzuki, Sho Kouyama
-
Publication number: 20200197385Abstract: A pharmaceutical composition for cancer treatment, comprising an Axl inhibitor and an anticancer drug (for example, a cytotoxic anticancer drug, a molecular target drug, an anti-CTLA-4 antibody, and the like), wherein the Axl inhibitor is a compound represented by the general formula (I): (wherein all of the symbols have the same meanings as set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, and which exhibits a strong antitumor effect, and therefore is useful for treatment of blood cancer and/or solid cancer.Type: ApplicationFiled: August 22, 2018Publication date: June 25, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Tomoko YASUHIRO, Kohei TANAKA
-
Patent number: 10676438Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.Type: GrantFiled: August 9, 2018Date of Patent: June 9, 2020Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
-
Patent number: 10675275Abstract: (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] can significantly suppress a decrease of a pain threshold compared to well-known TSPO antagonists, and thus can be an excellent prophylactic and/or therapeutic agent for fibromyalgia, fibromyalgia-associated diseases, and fibromyalgia-associated symptoms.Type: GrantFiled: January 8, 2016Date of Patent: June 9, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Seishi Katsumata, Katsukuni Mitsui, Yuya Ezaki
-
Patent number: 10676462Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: GrantFiled: August 14, 2019Date of Patent: June 9, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro